Oxaliplatin | 奧沙利鉑

MCE 國(guó)際站：Oxaliplatin

中文名：奧沙利鉑

CAS：61825-94-3

品牌：MedChemExpress (MCE)

存儲(chǔ)條件：4°C, protect from light

生物活性：Oxaliplatin 是一種DNA 合成 抑制劑。 Oxaliplatin 引起 DNA 交聯(lián)損傷，阻止 DNA 復(fù)制和轉(zhuǎn)錄并誘導(dǎo)細(xì)胞凋亡。奧沙利鉑可用于癌癥研究^[1][2][3]。 IC50 和目標(biāo)：IC50：DNA 合成^[1]

體外：Oxaliplatin（24-72 小時(shí)；2-128 μM；HCC、HCCLM3 和 Hep3B 細(xì)胞）抑制細(xì)胞生長(zhǎng)并誘導(dǎo)細(xì)胞凋亡^[1]。
Oxaliplatin（10 μM；15-240 分鐘； CEM 細(xì)胞 ) 誘導(dǎo)原發(fā)性和繼發(fā)性 DNA 損傷，包括 DNA 交聯(lián) (ISC) 和 DNA-蛋白質(zhì)交聯(lián) (DPC)^[2]。
奧沙利鉑（0.01 至 100 μM； 24 小時(shí)）有效抑制膀胱癌細(xì)胞系 RT4 和 TCCSUP、卵巢癌細(xì)胞系 A2780、結(jié)腸癌細(xì)胞系 HT-29、膠質(zhì)母細(xì)胞瘤細(xì)胞系 U-373MG 和 U-87MG，以及黑色素瘤細(xì)胞系 SK-MEL-2 和 HT- 144 的 IC₅₀ 分別為 11 μM、15 μM、0.17 μM、0.97 μM、2.95 μM、17.6 μM、30.9 μM 和 7.85 μM^[3]。

體內(nèi)：奧沙利鉑（5-10 mg/kg；腹腔注射；32 天；裸鼠）抑制腫瘤生長(zhǎng)^[1]。

熱銷產(chǎn)品：GNE-987  | L-DOPA  | Adenine  | Niraparib (tosylate)  | Rosuvastatin (Calcium)  | Caerulomycin A  | Fagomine  | Palmitic acid-13C16  | Canakinumab  | BODIPY 576/589

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Apoptosis

作用靶點(diǎn)：DNA/RNA Synthesis  |  Apoptosis

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻(xiàn)：

[1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71.

[2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63.

[3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.

[4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604

[5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50.

[6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.

[7]. Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92.

[8]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40.

[9]. Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347.